Next Article in Journal
Glomerular Macrophages in Human Auto- and Allo-Immune Nephritis
Next Article in Special Issue
Concentrated Secretome of Adipose Stromal Cells Limits Influenza A Virus-Induced Lung Injury in Mice
Previous Article in Journal
The Role of IL-9 Polymorphisms and Serum IL-9 Levels in Carcinogenesis and Survival Rate for Laryngeal Squamous Cell Carcinoma
Previous Article in Special Issue
Stem Cell Repair of the Microvascular Damage in Stroke

Stem Cells in Cardiovascular Diseases: 30,000-Foot View

Department of Medicine, and Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA
Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Author to whom correspondence should be addressed.
Academic Editors: Lilach O. Lerman and Amir Lerman
Cells 2021, 10(3), 600;
Received: 9 February 2021 / Revised: 1 March 2021 / Accepted: 3 March 2021 / Published: 9 March 2021
Stem cell and regenerative approaches that might rejuvenate the heart have immense intuitive appeal for the public and scientific communities. Hopes were fueled by initial findings from preclinical models that suggested that easily obtained bone marrow cells might have significant reparative capabilities; however, after initial encouraging pre-clinical and early clinical findings, the realities of clinical development have placed a damper on the field. Clinical trials were often designed to detect exceptionally large treatment effects with modest patient numbers with subsequent disappointing results. First generation approaches were likely overly simplistic and relied on a relatively primitive understanding of regenerative mechanisms and capabilities. Nonetheless, the field continues to move forward and novel cell derivatives, platforms, and cell/device combinations, coupled with a better understanding of the mechanisms that lead to regenerative capabilities in more primitive models and modifications in clinical trial design suggest a brighter future. View Full-Text
Keywords: stem cells; regenerative medicine; clinical trials; congestive heart failure; cardiomyopathy; angina stem cells; regenerative medicine; clinical trials; congestive heart failure; cardiomyopathy; angina
Show Figures

Figure 1

MDPI and ACS Style

Povsic, T.J.; Gersh, B.J. Stem Cells in Cardiovascular Diseases: 30,000-Foot View. Cells 2021, 10, 600.

AMA Style

Povsic TJ, Gersh BJ. Stem Cells in Cardiovascular Diseases: 30,000-Foot View. Cells. 2021; 10(3):600.

Chicago/Turabian Style

Povsic, Thomas J., and Bernard J. Gersh 2021. "Stem Cells in Cardiovascular Diseases: 30,000-Foot View" Cells 10, no. 3: 600.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop